243 related articles for article (PubMed ID: 21177315)
1. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
3. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
4. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400
[TBL] [Abstract][Full Text] [Related]
5. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
6. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M; Jin YY; Li G; Liu SM; Ji CD
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
[TBL] [Abstract][Full Text] [Related]
7. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
8. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
Liu JH; Li HW; Tong M; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
10. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
11. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
[TBL] [Abstract][Full Text] [Related]
12. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
13. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
[TBL] [Abstract][Full Text] [Related]
15. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
16. Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
Zhang D; Li Q; Qu HC; Yu T; Liu YR
Genet Mol Res; 2015 Aug; 14(3):9004-12. PubMed ID: 26345832
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1395-402. PubMed ID: 14693728
[TBL] [Abstract][Full Text] [Related]
18. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
19. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
